Ombrabulin

Drug Profile

Ombrabulin

Alternative Names: AC 7700; AVE-8062; AVE8062A; RPR258063

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Ajinomoto
  • Developer Sanofi
  • Class Amides; Antineoplastics; Small molecules
  • Mechanism of Action Tubulin polymerisation inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Soft tissue sarcoma; Solid tumours

Most Recent Events

  • 01 Nov 2014 Sanofi completes a phase I trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in France, Italy, United Kingdom (NCT01193595)
  • 30 Nov 2013 Sanofi completes a phase I trial in Solid tumours in Japan (NCT01293630)
  • 28 Feb 2013 Sanofi completes a phase I trial in Solid tumours in Europe (NCT00719524)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top